Gene Logic takes fresh look at Merck KGaA drugs

Merck Serono has enlisted Gene Logic to help breathe new life into abandoned drug candidates. The companies will seek alternative development paths for several Merck Serono drug candidates which have been discontinued or de-prioritized in clinical trials for reasons other than safety. Financial details of the deal weren't disclosed, but Gene Logic will receive success-based milestones and royalties.

Gene Logic's Drug Repositioning Program is designed to find alternative development paths for failed or stalled drug candidates. The program offers pharmaceutical partners an opportunity to bolster their pipelines with drug candidates that originated from their own R&D efforts. Other biotech and pharmaceutical companies that are giving Gene Logic's program a try include Abbott, Organon and Eli Lilly.

- check out this release on the agreement

Related Articles:
Gene Logic, Abbott strike development deal. Report
Gene Logic re-examines Organon candidates. Report
Gene Logic to give Lilly drugs fresh look. Report
Gene Logic cuts jobs at struggling genomics division. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.